Background:
The established risk factors for female breast cancer, including nulliparity, age at first birth, age at menarche, and age at menopause, do not adequately explain the occurrence pattern of this cancer. Therefore, additional factors need to be considered to advance our understanding of the causes of breast cancer. Evidence obtained from animals and humans indicates that the perinatal period may be particularly important. Our earlier studies, based on a subsample of the present investigation, suggested that factors thought to be positively associated with estrogen levels during pregnancy are positively associated with breast cancer risk. However, the associated confidence intervals (CIs) were generally wide, indicating considerable variability in the data. Purpose: We studied a large number of incident breast cancer case patients and evaluated several perinatal variables in relation to breast cancer risk. These variables included some not previously studied, such as gestational age and neonatal jaundice. We also investigated twin membership as a predictor variable and death from breast cancer, in addition to occurrence of breast cancer, as an alternative outcome variable. Methods: Birth records for all deliveries at five different hospitals in Sweden during the period from 1874 through 1961 were used to define a large cohort of women. Incident case patients with breast cancer in this cohort were ascertained through the National Cancer Registry or the Uppsala Regional Cancer Registry from 1958 through 1994. In a case-control study nested in the cohort, we abstracted data from birth records on 1068 women with incident breast cancer and on 2727 control subjects individually matched to the case patients on date of birth. We modeled the data through conditional logistic regression. All P values were derived from two-sided statistical tests. Results: We found a markedly reduced risk for breast cancer in women whose mothers had pregnancy toxemia (odds ratio [OR] = 0.41; 95% CI = 0.22-0.79) and an excess risk on women who had neonatal jaundice (OR = 2.16; 95% CI = 1.27-3.67) or who were born before 33 weeks of gestation (OR = 3.96; 95% CI = 1.45-10.81). Compared with the risk for breast cancer in the singleton, the risk for breast cancer in dizygotic twins was increased, although this increase was not statistically significant (OR = 1.72; 95% CI = 0.92-3.20). There was no evidence in these data for a statistically significant or substantial association of breast cancer risk with birth size indicators (i.e., weight and length at birth and placental weight). Conclusion and Implications: Because pregnancy toxemia is associated with low levels of estrogens and neonatal jaundice, severe prematurity, and dizygotic twins with high levels of estrogens, our findings suggest that estrogens and other hormonal factors, known to influence breast cancer risk in the adult, may also play a critical role during the intrauterine period. [J Natl Cancer Inst 1997;88:71-6]
In animal experiments, factors that cause cancer following exposures during adult life are also carcinogenic following exposure in utero (1) . In humans, evi-dence is overwhelming that endogenous estrogens in adolescence and adult life are important in the causation of breast cancer. Levels of estrogens, as well as of other hormones, are substantially elevated during pregnancy, when susceptibility to carcinogenesis is considered to be high. It is difficult, however, to directly evaluate whether variation in estrogen levels during pregnancy affects breast cancer risk in the offspring; instead, attempts have been made to use variables thought to be related to pregnancy estrogen levels as surrogates. Most of the relevant information concerns uncommon physiologic situations, such as twinning, or pathologic conditions, such as pregnancy toxemia that includes preeclampsia (a complication of pregnancy characterized by hypertension, edema, and/or proteinuria [presence of protein in the urine]) and eclampsia that has convulsions and coma as added complications to the preeclampsia.
There is evidence that estrogen levels in the mother and fetus are positively associated [for estradiol, r ‫ס‬ .27; for estriol, the correlation, higher (2)] and that administration of exogenous estrogens during pregnancy has definitive implications for the offspring (3). In addition, preeclampsia or eclampsia is characterized by low levels of pregnancy estrogens as well as of other hormones (4) (5) (6) (7) (8) . In contrast, estrogen levels are higher in women pregnant with dizygotic twins (9-11); extreme prematurity has also been reported to be associated with high estrogen levels in the offspring (12, 13) as well as in the mother (14) ; moreover, neonatal jaundice may be associated with high estrogen levels in the perinatal period (13, 15) . Birth size may also be positively associated with high levels of pregnancy estrogens, although most of the empirical evidence is limited to the low end of the corresponding distributions (4, (16) (17) (18) (19) . Finally, limited data suggest that older maternal age and primiparity (women who have had one pregnancy that resulted in a fetus that attained a weight of 500 g or a gestational age of 20 weeks) are associated with higher levels of pregnancy estrogens (20) (21) (22) .
Sweden offers unique opportunities to study the possible role of the intrauterine environment in the development of breast cancer, since pregnancy and birth records from the late 19th century onward can be linked to nationwide registers. In an earlier exploratory study (23), we found evidence that the intrauterine environment may indeed be an important factor. A markedly reduced risk for breast cancer in the offspring of women with pregnancy toxemia was the most striking finding. These epidemiologic leads paved the way for this expanded case-control study, nested in a well-defined cohort. We increased the number of incident breast cancer case patients from 458 to 1068 and control subjects from 1197 to 2727.
We studied a large number of incident breast cancer patients and control sujbects and evaluated several perinatal variables in relation to breast cancer risk. These variables included some not previously studied, such as gestational age and neonatal jaundice. We also investigated twin membership as a predictor variable and death from breast cancer, in addition to occurrence of breast cancer, as an alternative outcome variable.
Subjects and Methods

Setting
This is a case-control study nested in a cohort of women who delivered infants at one of five hospitals during the period from 1874 through 1961. In Sweden, all citizens have easy and equal access to health care. Only in unusual emergencies does a pregnant women contact a hospital outside her county of residence. Because there is no private inpatient treatment, hospital medical services, as a rule, are population based.
Our study population consisted of all women born at one of the five participating hospitals in the Uppsala-Ö rebro Health Care Region in Sweden during the period from 1874 through 1961 and who survived at least until January 1, 1958, when the Swedish National Cancer Registry was established. Since January 1, 1947, all inhabitants of Sweden have been assigned a 10-digit national registration number, a unique personal identifier (24) . The national registration number contains information about date of birth and the county in which the individual resided in 1947 or the county of birth for those born in 1947 or later. This number provides correct information about county of birth in 87.5% of all individuals born before 1947 (25) . A special code was used for immigrants until the early 1970s; it was then replaced by the code of the county where the individual first resided in Sweden. Underascertainment of case patients can occur only when a woman has moved out of her county of birth before 1947 and was later diagnosed with breast cancer.
All newly diagnosed malignant tumors in Sweden must be reported to the National Cancer Registry by both the physician who makes the diagnosis and the pathologist or cytologist who confirms the diagnosis to one of six regional cancer registries that further report the diagnosis to the National Cancer Registry (26) . All patients are entered in the National Cancer Registry with their national registration number. At the time of this study, the National Cancer Registry was complete through 1992 and the Uppsala Regional Cancer Registry was complete through 1994. Through the Swedish Death Registry, we identified patients who survived the disease by time of censoring of the follow-up information (December 1994), thus enabling us to evaluate both incidence of an mortality from breast cancer as outcome measures.
Case Patients and Control Subjects
Potentially eligible case patients were all women in the National Cancer Registry ) and the Uppsala Regional Cancer Registry (1993-1994) who had been diagnosed with invasive breast cancer and had the code for any of the four relevant counties in the Uppsala-Ö rebro Health Care Region in their national registration number. We were able to establish the place of the patient's birth and her family name at birth through the parish in which each patient lived when her breast cancer was diagnosed. We identified five hospitals (Avesta, Eskilstuna, Falun, Sundsvall, and Uppsala) with similar systems for storing the delivery charts. The maternity wards at different hospitals began to operate or started to use maternity charts at different times (ranging from 1874 in Uppsala to 1941 in Avesta). Women with breast cancer who were not born at any of these hospitals during the study period were excluded, since they were not part of the study base.
There were 1068 eligible case patients; all were included. For each case patient, we selected as potentially eligible control subjects, females born to the first three mothers who were admitted to the corresponding hospital after the case patient's mother. Potential control subjects were linked to the Swedish Death Registry through 1994 in order to establish that they were alive and therefore at risk at the time of diagnosis of the corresponding case patient. To ascertain that a potential control subject had not been diagnosed with breast cancer at the time of diagnosis of the corresponding case patient, we looked at records in the parish of residence and, on the basis of the national registration number, in the Swedish Cancer Registry and the Uppsala Regional Cancer Registry. Of the 3204 potentially eligible control subjects, 477 were excluded; thus, 2727 were eventually eligible and were matched to the incident breast cancer case patients.
To assess death from as well as occurrence of breast cancer as an outcome, we identified by linkage with the Swedish Death Registry 286 women among the case patients who had breast cancer as their underlying cause of death. In a similar way, we identified 701 control subjects who were alive at the time that their individually matched case patients died.
The investigation was approved by the Human Subjects Committee of Harvard School of Public Health in accord with an assurance filed with an approved by the U.S. Department of Health and Human Services.
Data Collection
At the five participating hospitals, the maternity wards used charts that contained a variable amount of information over different time periods. However, the following information was recorded at all hospitals throughout the study period: for the mothermarital status, parity, age at delivery, education and/or profession of the father and mother, and any medical problems encountered during pregnancy or af-ter delivery such as preeclampsia or eclampsia (pregnancy toxemia); for the child-singleton or multiple birth, gestational age, birth length and weight, and presence of jaundice. Although variation in the phrasing of the questions did exist, it was minimal and could not have affected the study validity because it was both nondifferential and accounted for by the matched design. Certain information such as placental weight and age at menarche for the mother, existed for only some of the hospitals during certain time periods. We assessed socioeconomic status on the basis of the father's or single mother's education in the following categories: high (college education), medium (white collar workers and farm owners with no college education), and low (blue collar workers and farmhands).
The charts were meticulously filled out by the midwives and nurses, and there were few instances of missing information when a specific variable was available in the chart; the frequency of missing data for an item that was part of the record in any hospital at any time period was less than 2%. Gestational age was assessed from the 1st day of the last menstrual period. A newborn was considered severely premature when gestational age was less than 33 weeks (27) [the midpoint between gestational ages that define prematurity and extreme prematurity according to the International Classification of Diseases, 9th revision (28)]. Multiple birth was characterized as either monozygotic or dizygotic by the midwives; we have used their judgment as the operational definition for this study.
Statistical Analyses
The statistical analysis was undertaken by modeling the data through conditional logistic regression (29) . The computing program PROC PHREG of the SAS statistical software was applied in the modeling (30) . Separate analyses were conducted to assess the predictors of incidence of and death from breast cancer. For the latter analysis, case patients were only women who had died of breast cancer as the underlying cause of death, but there were also exclusions from control subjects of those who did not survive until the age of death of the corresponding case patients. Trend test was derived by fitting ordinal variables directly in the models and examining the significance of the coefficients by a chi-squared test. The level of statistical significance was set at P<.05 (two-sided).
Results
The mean age at diagnosis among all women with breast cancer was 49.9 years, and 582 (54.4%) were younger than 50 years. Table 1 describes the distribution of case patients and population-based, agematched control subjects according to the available maternal and perinatal characteristics.
Conditional logistic regressionderived, mutually adjusted odds ratios (ORs) for breast cancer occurrence in relation to maternal and perinatal characteristics are presented in Table 2 †Low ‫ס‬ blue collar workers and farmhands; medium ‫ס‬ white collar workers and farm owners with no college education; high ‫ס‬ college education.
‡Preeclampsia is a complication of pregnancy characterized by hypertension, edema, and/or proteinuria (presence of protein in the urine), and eclampsia has convulsions and coma added to the preeclampsia complication.
§Cutoff values for quartiles were 49, 51, and 52 cm.
Cutoff values for quartiles were 550, 630, and 730 g.
breast cancer (OR ‫ס‬ 1.72; 95% CI ‫ס‬ 0.92-3.20), although the result was of borderline significance. In this dataset, none of the birth size indicators (birth weight, birth length, and placental weight) were significantly related to breast cancer risk in the offspring. However, adjusting for placental weight increased the positive trends of breast cancer risk with birth weight (P value of .56 changed to .25) and birth length (P value of .45 changed to .23). About half of the case patients and matched control subjects were derived from the Uppsala University Hospital, and about 80% of the Uppsala University Hospital case and control subjects (43% of the total) were included in a previous report (23) , although at that time information concerning prematurity and neonatal jaundice had not been collected and twins were excluded from the study base. Moreover, maternal age at menarche was available in the Uppsala University Hospital records but not in the records of the other hospitals, which made it necessary to exclude this variable from the current analyses. When all case patients and control subjects were analyzed (Table 2) , the adjusted ORs for the factors that were significantly associated with breast cancer risk had the following values, respectively, when subjects from the Uppsala University Hospital and those from the four other hospitals were separately considered: for maternal preeclampsia or eclampsia, 0.39 (95% CI ‫ס‬ 0.17-0.89) and 0.48 (95% CI ‫ס‬ 0.16-1.44); for neonatal jaundice, 2.03 (95% CI ‫ס‬ 1.15-3.59) and 4.24 (95% CI ‫ס‬ 0.94-19.07); and for severe prematurity (<33 weeks), 5.01 (95% CI ‫ס‬ 1.38-18.19) and 3.06 (95% CI ‫ס‬ 0.56-16.72). With respect to maternal age and dizygotic twins, for which the results approached statistical significance in the total set, findings were also similar in the two subsets. For weight and length at birth, for which the results were far from statistically significant in the total set, the findings were weakly and nonsignificantly positive in both subsets. Placental weight was noted in the records of only a small minority of subjects born in hospitals other than the Uppsala University Hospital. These data are presented to demonstrate the consistency of the pattern of the observed association between the two data subsets.
In 10 same-sex multiple births (nine twins and one triplet), one member has developed breast cancer and the other(s) has survived to the time of diagnosis of breast cancer in the case patient. With respect to birth weight, the sibling that developed breast cancer was heavier in eight case patients and identical in the two others. The difference was statistically significant (P < .01), but it was still data derived and based on a small number of subjects.
We have analyzed the data (not shown) by menopausal status, and we have also restricted the analysis to women who died of breast cancer and their matched control subjects who were at risk for this outcome at the age of the corresponding case patients. The results of these analyses were similar to those reported in Table 2 . There was no evidence of modification by (interaction with) age at diagnosis of breast cancer in relation to the study factors, although there were very few women who developed breast cancer at very young ages.
Discussion
The hypothesis that perinatal factors are involved in the development of breast cancer in women and the possibility that pregnancy estrogens might contribute to this association have been evaluated in a number of studies (31-36) using different methodologies. Collectively, the results of these studies are compatible with perinatal factors being associated with breast can- *From a model including all the variables in the table with the exception of birth length and placental weight, which were entered in place of birth weight in separate models.
†Reference category. ‡Preeclampsia is a complication of pregnancy characterized by hypertension, edema, and/or proteinuria (presence of protein in the urine), and eclampsia has convulsions and coma added to the preeclampsia complications.
§Gestational age <33 weeks.
cer risk in the offspring, and the hypothesis that pregnancy estrogens are the underlying factors cannot be rejected. Nevertheless, the findings from these studies have not been altogether consistent, possibly because the relevant biological variables could not be operationally captured. This case-control study was nested in a well-defined cohort in accordance with explicitly defined procedures. In this design, selection into the study base cannot introduce bias because it is unrelated to outcome ascertainment. Moreover, information bias away from the null hypothesis is very unlikely, since exposure misclassification occurs before outcome ascertainment and can only be nondifferential. Confounding by risk factors for breast cancer in adult life is theoretically possible, but the established risk factors for breast cancer have not been shown to be related to the perinatal exposures under consideration; in any case, there was no information for adult life risk factors for breast cancer in these data.
In an earlier exploratory study (23) based on 458 case patients and 1197 matched control subjects, the only statistically significant finding was an inverse association between breast cancer risk and maternal pregnancy toxemia, whereas birth size indicators were not significantly positively associated with breast cancer risk in the offspring. The findings of our expanded study are essentially identical with respect to pregnancy toxemia. (Introduction of maternal age at menarche into the model reduces the point estimate in the subjects from the Uppsala University Hospital from 0.39 to 0.20, but this potential confounding variable was not available for most women born in other hospitals.) However, the weak pattern of increasing breast cancer risk with birth size indicators remained weak in the total dataset. Adjusting for placental weight increased in absolute terms the association between breast cancer risk and birth weight and birth length. This result could have been generated by chance or could have been due to placental enlargement being, in some instances, an adoptive response to compensate for embryonic growth retardation (37) . No results have been previously reported from this dataset with respect to multiple births, gestational age, or neonatal jaundice.
For seven of the nine variables evaluated in this study (birth weight, birth length and placental weight are alternative indicators of birth size), there is some evidence of an association with pregnancy estrogens; the exceptions were maternal socioeconomic status and maternal marital status, for which no such information was available. With respect to pregnancy toxemia, the evidence is quite strong that it is associated with low levels of pregnancy estrogens (4) (5) (6) (7) (8) , as is the evidence for an inverse association with breast cancer in this dataset. Estrogen levels are higher in the women with twin pregnancies (9-11), and we found evidence that female members of dizygotic twins are at higher risk for breast cancer, as has also been reported by others (38, 39) . Because dizygotic twins tend to have two placentas and monozygotic twins to have one placenta, it has been assumed that the higher levels of pregnancy hormones generally observed in women with twin pregnancies are primarily linked to dizygotic twins.
Severe prematurity and neonatal jaundice were markedly and significantly associated with breast cancer risk in our study. Although reporting of neonatal jaundice was less common in hospitals other than the Uppsala University Hospital, the association was, if anything, stronger in data from these other hospitals. Clearly, these novel epidemiology findings need to be confirmed in other studies. Few studies have examined these perinatal variables in relation to pregnancy estrogens, but the evidence (limited as it is) supports a positive association. Extremely premature birth, a rare occurrence, is associated with high estrogen levels in the mother (13, 14) or the offspring (12), even though, in general, estrogens as growth factors are associated with higher birth size. It would seem that pregnancy estrogens, if they are indeed responsible for the observed patterns, may have several manifestations in distinct, clinically observable variables. High estrogen levels have also been noted among infants with jaundice (13, 15) , possibly as a result of impaired metabolism in the liver.
Older maternal age has been associated with high levels of pregnancy estrogens (20, 22) and was directly related to breast cancer risk in this study. Although fetal growth retardation is clearly associated with low levels of pregnancy estrogens (4, (16) (17) (18) (19) , it is not known whether the association extends to the usual range of fetal growth. In our study, there was little evidence for a positive association between birth size and breast cancer risk in the offspring, and there was limited power to examine whether an association could be confined to the lower tail of the birth size distributions.
Overall, our results strongly suggest that perinatal factors are involved in the development of breast cancer in the offspring, and they do not refute the hypothesis that pregnancy estrogens may be directly or indirectly implicated. The evidence with respect to pregnancy estrogens is not overwhelming, but this should be expected even if they played a key role, since the available study variables are likely to be only moderalty correlated with pregnancy estrogens and can serve only as surrogates of suboptimal validity. Moreover, the cause of breast cancer is clearly multifactorial, and the endocrine milieu during pregnancy is too complex to allow the emergence of powerful associations through unidimensional indicators. Finally, our breast cancer study sample is weighted toward younger women, and the results may not apply to older women with this cancer. Further studies of pregnancy toxemia, prematurity, and neonatal jaundice and their hormonal correlates could improve our understanding of early events in the development of human breast cancer.
